The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a platform technology, iTANK (ELC-001 ) for further immune enhancement of treatments in said field.
Preclinical POC
Glp tox
Phase I/II
NET: Neuroendocrine tumors
NHL: Non-Hodgkins lymphoma
GBM: Glioblastoma Multiforme (brain tumor)
PoC: Proof-of-Concept
GLP: Good Laboratory Practice

Clinical trials

ELC-100 is currently being tested in a clinical phase I/II-trial, sponsored by Uppsala University, which is planned in two steps (ClinicalTrials.gov Identifier: NCT02749331) where the main goal of step one is to determine safety and the maximum tolerable dose to be tested in step two in an additional 12 patients.

The first step of the study has four dose levels with three patients at each level. In addition to looking at side effects, the patients are also examined for efficacy. A complete treatment consists of four injections over the course of about seven weeks. ELC-100 is injected using X-ray technology via blood vessels from the groin into the liver. The patient is evaluated one month later with combined advanced medical technology (CT, MRI, PET). At present, six, out of a total of 12 planned patients have been treated.

Although it is too early to draw any conclusions from the study, data reported so far by Uppsala University show some promising signs of efficacy.

* https://clinicaltrials.gov/ct2/show/NCT02749331?term=advince&draw=2&rank=1
Shaking hands in agreementment